RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis Jul 1, 2015
RepliCel Life Sciences Inc. Announces Closing of Brokered and Non-brokered Private Placement Jun 27, 2015
Resverlogix Reports on the Beneficial Effects of RVX-208 on Glucose Metabolism in Prediabetes Mellitus at the American Diabetes Association’s (ADA) Scientific Sessions in Boston, MA Jun 9, 2015
RepliCel Life Sciences Announces Participation in 23rd World Congress of Dermatology, Vancouver, BC Jun 6, 2015
RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference May 21, 2015
Resverlogix and China-based Shenzhen Hepalink Pharmaceutical Co., Ltd. Announce a Combination Licensing and Equity Arrangement Apr 28, 2015
RepliCel Life Sciences Receives Approval to Conduct Clinical Trial for Patients with Chronic Achilles Tendinosis Apr 16, 2015
RepliCel Life Sciences Receives TSX Venture Exchange Approval to Extend Warrant Expiry Dates Apr 8, 2015
